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Ethyl 3-bromoimidazo[2,1-b]thiazole-5-carboxylate (7)
To a solution of 4 (5.00 g, 27.9 mmol) in DMF (50 ml) was added N,N-dimethylformamide dimethyl acetal (7.44 ml, 55.8 mmol) at room temperature. After stirring at 70 °C for 1 h, the reaction mixture was diluted with water (500 ml), and the aq. layer was extracted with ethyl acetate (250 ml x 2). The organic layer was washed with brine (500 ml), and the combined organic extracts were dried over Na 2 SO 4 and concentrated. The residue was purified by flash column chromatography (SiO 2 , hexane / ethyl acetate) to give compound 5 (5.50 g, 84%) as brown solids. 1 HPLC purity = 99.4% (Rt = 3.87 min).
Ethyl 3-(4-bromophenyl)imidazo[2,1-b]thiazole-5-carboxylate (8i)
Synthetic procedure was followed as described for compound 7. HPLC purity = 99.8% (Rt = 5.07 min).
Ethyl 3-(3'-tolyl)imidazo[2,1-b]thiazole-5-carboxylate (8b)
Synthetic procedure was followed as described for compound 8a. 
Ethyl 3-(cyclohex-1-en-1-yl)imidazo[2,1-b]thiazole-5-carboxylate (8e)
Ethyl 3-(4'-ethylphenyl)imidazo[2,1-b]thiazole-5-carboxylate (8f)
Ethyl 3-(4'-chlorophenyl)imidazo[2,1-b]thiazole-5-carboxylate (8h)
Synthetic procedure was followed as described for compound 8a. HPLC purity = 99.4% (Rt = 5.29 min).
5-Methyl-3-(4'-tolyl)imidazo[2,1-b]thiazole (3)
To a solution of 8a (100 mg, 0.349 mmol) in THF (5 ml 
N-Phenethyl-3-(4'-tolyl)imidazo[2,1-b]thiazole-5-carboxamide (13a)
To 
N-(3''-Chlorophenethyl)-3-(4'-tolyl)imidazo[2,1-b]thiazole-5-carboxamide (13b)

S12
Synthetic procedure was followed as described for compound 13a. (Rt = 5.02 min).
N-(2''-(Benzo[d][1'',3'']dioxol-5''-yl)ethyl)-3-(4'-tolyl)imidazo[2,1-b]thiazole-5-carboxamide (13c)
Synthetic procedure was followed as described for compound 13a. 
{3-(4'-bromophenyl)imidazo[2,1-b]thiazol-5-yl}methanol (14)
To a solution of 8i 
5-(azidomethyl)-3-(4'-bromophenyl)imidazo[2,1-b]thiazole (15)
{3-(4'-bromophenyl)imidazo[2,1-b]thiazol-5-yl}methanamine (16)
To a solution of 15 (350 mg, 1.05 mmol) in THF (10 ml) and water (0.189 ml, 10. 
1-[{3'-(4''-bromophenyl)imidazo[2,1-b]thiazol-5'-yl}methyl]-3-phenylurea (17a)
S14
To a solution of 16 (40.0 mg, 0.13 mmol) in THF (1.0 ml) were added i-Pr 2 NEt (0.028 ml, 0.17 mmol) and PhNCO (0.017 ml, 0.16 mmol) at room temperature. After stirring at the same temperature for 2 h, the reaction mixture was quenched by sat. NaHCO 3 aq. (10 ml), and the aq. 
1-benzyl-3-[{3'-(4''-bromophenyl)imidazo[2,1-b]thiazol-5'-yl}methyl]urea (17b)
Synthetic procedure was followed as described for compound 17a. 463.0199, found 463.0199 (∆ = 0.00 mmu); HPLC purity = 98.7% (Rt = 3.96 min).
1-[{3'-(4''-bromophenyl)imidazo[2,1-b]thiazol-5'-yl}methyl]-3-cyclohexylurea (17c)
Synthetic procedure was followed as described for compound 17a. (benzo[d][1,3]dioxol-5'-yl)-3-[{3''-(4'''-bromophenyl)imidazo[2,1-b 
1-
1-((3''-(4'''-bromophenyl)imidazo[2,1-b]thiazol-5''-yl)methyl)-3-(3'-methoxyphenyl)urea (17e)
Synthetic procedure was followed as described for compound 17a. 
1-((3''-(4'''-bromophenyl)imidazo[2,1-b]thiazol-5''-yl)methyl)-3-(4'-methoxyphenyl)urea (17f)
S16
1-((3''-(4'''-bromophenyl)imidazo[2,1-b]thiazol-5''-yl)methyl)-3-(4'-cyanophenyl)urea (17g)
2) Purification method of recombinant IDO1 protein
Human IDO1 was cloned into pET-28a vector (Novagen), expressed and purified by the published procedures 1) except for using LB medium containing 0.75mM -aminolaevulinic acid. The level of heme incorporation achieved was ~78% based on an A406/A280 ratio of 2.2 for fully heme-incorporated IDO1 1) .
3) Biological assay method
IDO1 enzyme assay were performed as described before 2) with some modifications. Briefly, test compounds were added to 150 μL of reaction mixture containing 50 nM recombinant IDO1, 100 μM L-Trp, 20 mM ascorbate, 10 μM methylene blue and 100 μg/mL catalase in 50 mM potassium phosphate buffer (pH 6.7). After incubation at room temperature for 30 min, the reactions were stopped by adding 30μL of 30% (w/v) trichloroacetic acid. Reaction mixtures were incubated at 65 °C for 15 min to convert N-formylkynurenine to kynurenine and then mixed with 180 μL of 2% (w/v) para-dimethylaminobenzaldehyde in acetic acid. The yellow color generated from the reaction S17 with kynurenine was measured at 480 nm using SPECTRA MAX M2 (Molecular Devices).
4) X-ray crystallography
Prior to crystallization with compounds, the sample buffer was exchanged to buffer C (25 mM MES pH 6.5, 25 mM NaCl, 2 mM compound) using a PD-10 Desalting Column (GE Healthcare) and concentrated by centrifugation. This exchange procedure to remove buffer contained TCEP and add compound at the same time was essential for IDO1-compound complex crystallization. IDO1 was concentrated to 20-40 mg/ml in a buffer containing 10 mM MES (pH 6.5), 25 mM NaCl, and 2 mM compound. Crystals of IDO1-compound complex were obtained by vapor diffusion method using reservoir solution (10% polyethylene glycol 20,000, 2% Dioxane, 100 mM Bicine, pH 9.0). Crystals were grown in a few days at 20°C in the space group P2 1 2 1 2 1 . The crystals were cryoprotected by soaking in the reservoir with 30% xylitol. Diffraction data sets were collected using BL41XU beamline at SPring-8 (Hyogo, Japan) or PXI beamline at SLS (Villigen, Swiss). The data were reduced and scaled with HKL2000 3) or iMosflm 4) and SCALA 5) of the CCP4 program suites 6) . The X-ray crystal structures were solved by molecular replacement method with Molrep 7) of the CCP4 program suites 6) using the phenyl imidazole complex of IDO1 (PDB ID: 2D0T) as the search model.
The structures were refined through an iterative procedure utilizing REFMAC 8) followed by model building in COOT 9) . The dictionary files for the ligands were prepared using AFITT (OpenEye Scientific Software, USA). Data collection and refinement statistics are shown in Table S1 . All structural figures were prepared with PyMOL 10) . S18 The values in parentheses are for the highest-resolution shell. Rmerge is  Rcryst is  |Fo -Fc|/ Fo, where Fo and Fc are the observed and calculated amplitude, respectively; Rfree is the same statistic calculated over a subset, 5%, of all the data that have not been used for refinement.
Ramachandran statistics as defined by RAMPAGE 11) 
